Completion of Facility Enables Initiation of Phase 3 Clinical Trial of Nepafenac in Patients Undergoing Cataract Surgery
AUSTIN, Texas, Sept. 12, 2023 /PRNewswire/ — Mati Therapeutics Inc. (“Mati”) announced that it has completed and now occupies a facility dedicated to manufacturing all products formulated in Mati’s proprietary Evolute® sustained ocular drug delivery platform. The 10,000 square foot facility is located in Bryan, Texas and has the capacity to fulfill all manufacturing needs for both development and commercial purposes for the foreseeable future. Mati engineers designed, built, and programmed each of the robotic devices used in a multi-step process to manufacture each product in the Evolute® platform.
“Following pandemic-related disruptions to global…
Source link
